Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals Limited announced a webinar to discuss the strong initial demand and performance of their newly launched product, Sofdra. This event, scheduled for July 8, 2025, will be led by key executives and aims to provide stakeholders with insights into the product’s market reception and its implications for the company’s growth and industry standing.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for Sofdra, a novel treatment for primary axillary hyperhidrosis, marking it as the first new chemical entity approved for this condition.
Average Trading Volume: 9,602,484
Technical Sentiment Signal: Sell
Current Market Cap: A$607.9M
See more data about BOT stock on TipRanks’ Stock Analysis page.